Advancing the personalization of medicine through novel biomarkers and innovative technologies

Timothy A. Yap  
Royal Marsden Hospital and The Institute of Cancer Research, UK

Abstract
The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this talk, I will discuss current approaches and propose strategies, including novel technologies & platform advances in personalized medicine that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.

Biography
Dr Timothy Yap BSc (Hons) MBBS MRCP PhD is a National Institute for Clinical Research Academic Clinical Lecturer in Medical Oncology at the Royal Marsden Hospital and The Institute of Cancer Research in London, UK.

He first gained a first-class BSc (Hons) degree and attained his Medical degree from Imperial College, London, before undertaking his general medical specialist training in Oxford and specialist oncology training in London. He also completed a Ph.D. in molecular pharmacology at The Institute of Cancer Research in London. Dr. Yap is primarily involved in translational cancer research and drug development, with his main focus on the discovery of targeted therapies and accelerating their development with novel predictive and pharmacodynamic biomarkers in order to personalize medicine.

Dr Yap has won multiple awards for his research, and has authored more than 60 peer-reviewed scientific publications and more than 70 published abstracts. He has also delivered multiple lectures in major symposiums at international medical conferences.

Timothy.Yap@icr.ac.uk